SCHEMBL874453

SCHEMBL874453

O=C(O)c1cnccc1Oc1ccc(Br)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.48
PTGS2 P35354 2/20 0.48
KDM4C Q9H3R0 4/20 0.43
ICAM1 P05362 2/20 0.41
SELE P16581 2/20 0.41
CDC7 O00311 1/20 0.41
DYRK3 O43781 1/20 0.41
ROCK2 O75116 1/20 0.41
MAP4K4 O95819 1/20 0.41
FYN P06241 1/20 0.41
CDK1 P06493 1/20 0.41
PIM1 P11309 1/20 0.41
PRKACA P17612 1/20 0.41
VCAM1 P19320 1/20 0.41
CDK2 P24941 1/20 0.41
FLT4 P35916 1/20 0.41
MAPK9 P45984 1/20 0.41
CSNK1A1 P48729 1/20 0.41
CSNK1D P48730 1/20 0.41
CLK2 P49760 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2657045 0.85 KDM4C (0.56) PTGS1PTGS2KDM4CGPBAR1ALDH1A1
SCHEMBL10237798 0.84 GPBAR1 (0.51) PTGS1PTGS2KDM4CICAM1SELE
SCHEMBL15912467 0.84 PTGS1 (0.51) PTGS1PTGS2ICAM1SELECDC7
SCHEMBL851190 0.81 CA12 (0.58) KDM4CICAM1SELEVCAM1GPBAR1
SCHEMBL874102 0.80 PTGS1 (0.48) PTGS1PTGS2ICAM1SELEGPBAR1
SCHEMBL7921365 0.77 CTNNB1 (0.56) PTGS1PTGS2ALDH1A1KDM4EMEN1
SCHEMBL47045 0.73 AKR1C3 (0.47) ICAM1SELECDC7DYRK3ROCK2
SCHEMBL742273 0.73 CTNNB1 (0.65) PTGS1PTGS2KDM4CICAM1SELE
SCHEMBL571110 0.73 POLB (0.72) FYNALDH1A1KDM4EMEN1MAPT
SCHEMBL2371063 0.73 KDM4E (0.48) ALDH1A1KDM4EPOLBMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120157448-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES GENENTECH, INC. 2012-06-21 US disclosed
WO-2012071458-A1 HETEROCYCLIC INHIBITORS OF BETA - SECRETASE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. (US) 2012-05-31 WO disclosed
US-20120083501-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. 2012-04-05 US disclosed
WO-2012040641-A2 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. (US) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157448-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES BACE1, PSEN1, PSEN2 PTGS1 974/4885PTGS2 1598/4885KDM4C 4300/4885
US-20120083501-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES BACE1, PSEN1, PSEN2 PTGS1 974/4885PTGS2 1598/4885KDM4C 4300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.